Print

Concert Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease  
2/19/2013 9:26:44 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. announced today that it has completed enrollment of patients in a Phase 2 clinical trial evaluating CTP-499 for the treatment of diabetic kidney disease. CTP-499 is intended to slow progression of kidney damage in diabetic kidney disease and be additive to the current standard of care, which is treatment with an angiotensin converting enzyme inhibitor (ACEi) and/or an angiotensin receptor blocker (ARB). Concert expects to report top-line results from the Phase 2 study during the second-half of 2013.
//-->